FTSE 100 held back by AstraZeneca trial setback
- Center-left1
- Center-right2
no rewrites detected — all voices distinct
Summary
FTSE 100 held back by AstraZeneca trial setback. The fall in AstraZeneca, the second highest weighted firm in the FTSE 100, offset gains in mining stocks as metal prices rallied. AstraZeneca said Wainua, whose generic name is eplontersen, was being tested in patients with transthyretin-mediated amyloid cardiomyopathy.
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
FTSE 100 held back by AstraZeneca trial setback.
reliability moderate3/3 sources
Reported detailssecondary facts, each attributed to its source
The fall in AstraZeneca, the second highest weighted firm in the FTSE 100, offset gains in mining stocks as metal prices rallied.
according to The IndependentAstraZeneca said Wainua, whose generic name is eplontersen, was being tested in patients with transthyretin-mediated amyloid cardiomyopathy.
according to The Independent
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources3 sources cross-checked
Center-left1
Center-right2